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cedure could be performed with acceptable mortality,
although it had a higher morbidity, especially when
done in patients with benign disease.3-7 We review our
9 years of experience with this operation to evaluate the
postoperative outcomes and long-term results of vari-
ous indications.
Patients and methods
Between January 1990 and December 1998, 66 consecu-
tive patients underwent completion pneumonectomy for a
variety of pulmonary diseases in the Department of Thoracic
Surgery and Endoscopy of Ruhrlandklinik in Essen-
Heidhausen. This represented 6.8% of all pneumonectomies
(967 cases) done during the same period. There were 44
male and 22 female patients, with an average age of 57 years
(range, 37-72 years). Right completion pneumonectomy was
done in 33 patients, and left completion pneumonectomy
was done in 33 patients.
First operation. Indications for initial surgical procedure
were benign diseases in 10 patients (bronchiectasis, 5;
Completion pneumonectomy refers to a procedure toremove what is left of a lung partially resected dur-
ing a previous operation. Although it is technically
demanding and associated with significant morbidity
and mortality,1 indications for malignant disease have
increased with regard to the increasing frequency of
lung cancer, the widespread use of limited resection for
early lung cancer, and the increasing demands for pul-
monary resection for pulmonary metastases. Since the
first detailed report by McGovern and colleagues,2
many reports have been published to examine the risk
and outcome of this technique. In most series the pro-
Objective: Completion pneumonectomy is reported to be associated with
high morbidity and mortality, especially when done in patients with benign
disease. We review our 9 years of experience with this operation to evaluate
the postoperative outcome and long-term results of various indications.
Methods: Between January 1990 and December 1998, 66 consecutive
patients underwent completion pneumonectomy (6.8% of all pneumonec-
tomies), and their cases were retrospectively reviewed. The indication was
benign disease in 17 patients and malignant disease in 49 patients. In patients
with malignant indications there were 14 local recurrences, 4 second prima-
ry tumors, 5 metastatic diseases, and 26 indications because of incomplete
initial resection.
Results: There were no intraoperative deaths, and the postoperative mortali-
ty rate was 7.6%. Complications were encountered in 32 (53%) patients,
without any significant difference between benign indication (71%) and
malignant indication (47%; P = .0923). Bronchopleural fistula was encoun-
tered in 5 (7.6%) patients, and empyema was encountered in 7 (11%)
patients. The actuarial 5-year survival was 57% for all patients, 65% for
those with benign indications, and 54% for those with malignant indications
(60% for local recurrence, 50% for second primary tumor, and 56% for
incomplete resection), without any difference between benign and malignant
indications (P = .9478).
Conclusions: Completion pneumonectomy can be performed with acceptable
mortality and morbidity, even in patients with benign disease. Patients with
preoperative infection can be managed with bronchial stump covering and
adequate postoperative drainage. Although complications are common, they
can successfully be managed with a proper understanding of them. (J Thorac
Cardiovasc Surg 2001;121:484-90)
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tuberculosis, 3; bronchopulmonary aspergillosis, 1; and
pulmonary dermoid cyst, 1) and malignant diseases in 56
patients (primary lung cancer, 46; metastatic lung cancer,
7; carcinoid tumor, 3). TNM classification of the patients
with primary lung cancer was T1 N0 in 4 patients, T2 N0
in 14 patients, T1 N1 in 2 patients, T2 N1 in 17 patients, T2
N2 in 1 patient, T3 N0 in 1 patient, T3 N1 in 3 patients, T2
N3 in 3 patients, and T4 N0 in 1 patient. The initial surgi-
cal procedure was a right upper lobectomy in 17 patients, a
right lower lobectomy in 5 patients, a right upper sleeve
lobectomy in 3 patients, a right upper bilobectomy in 2
patients, a right lower bilobectomy in 3 patients, a right
partial resection in 3 patients, a left upper lobectomy in 14
patients, a left lower lobectomy in 14 patients, a left seg-
mental resection in 3 patients, and a left partial resection in
2 patients. Five (7.6%) patients underwent postoperative
radiation therapy up to 60 Gy.
Completion pneumonectomy. The indication for comple-
tion pneumonectomy was benign disease in 17 patients
(bronchiectasis, 7; resistant pneumonia, 3; bronchopleural
fistula [BPF], 2; lung abscess, 2; lung hemorrhage, 2; and
tuberculosis, 1) and malignant disease in 49 patients. In the
group with malignant disease, including carcinoid tumor,
there were 14 local recurrences, 4 second primary tumors, 5
metastatic diseases, and 26 indications because of incomplete
initial resection revealed by means of postoperative patholog-
ic findings (R1). The relationship between the first and sec-
ond operation is shown in Table I.
Local recurrence. Local recurrence is defined as a second
lung malignancy with the same histologic features and the
same anatomic site, occurring within 2 years of the first oper-
ation.5 Stump recurrence is regarded as a local recurrence
regardless of the time interval. Among the patients, 9 had ade-
nocarcinomas, 1 squamous cell carcinoma, 1 adenosquamous
cell carcinoma, 1 large cell carcinoma, and 2 carcinoid
tumors. TNM classifications at initial operation were T1 N0
M0 in 2 patients, T2 N0 M0 in 8 patients, and T1 N1 M0, T2
N1 M0, T2 N2 M0, and T3 N1 M0 in 1 patient each. The
mean interval between the first and second operation was 34
months (range, 3-74 months).
Second primary tumor. Second primary tumor is defined as
a second malignancy with a different histologic type, differ-
ent anatomic site, and occurrence after more than 2 years
from the first malignancy.8 Histologic and TNM classification
of the included patients were as follows (initial histology and
stage): adenocarcinoma, T2 N0 (adenocarcinoma, T2 N0 14
years before); adenocarcinoma, T2 N0 (squamous cell carci-
noma, T1 N0 4 years before); and squamous cell carcinoma,
T3 N1 (squamous cell carcinoma, T2 N1 9 years before). A
case of primary lung cancer (adenocarcinoma, T2 N1 M1)
after pulmonary resection of metastatic testicular carcinoma 4
years before was included for a convenience.
Metastatic lung tumor. Primary tumor included pharyngeal
cancer in 2 patients and colon cancer, rectal cancer, and
malignant schwannoma in 1 patient each. The mean interval
between the first and second operations was 16 months
(range, 4-25 months). All patients were free from metastasis
of the hilar and mediastinal lymph nodes, except for one.
Incomplete initial resection. Because of the incomplete ini-
tial resection revealed by postoperative pathology (R1), some
patients underwent completion pneumonectomy, although
this indication has recently diminished because of use of
intraoperative frozen sections. The reason for incomplete ini-
tial resection was due to positive bronchial margin in 15
patients and positive N1 lymph node in 11 patients, whose
extracapsular infiltration could not be found intraoperatively
but was proven pathologically. These included 11 adenocar-
cinomas, 12 squamous cell carcinomas, 1 adenosquamous
cell carcinoma, 1 large cell carcinoma, and 1 adenoid cystic
carcinoma. TNM classification of the patients was T1 N0 in
2 patients, T2 N0 in 5 patients, T1 N1 in 1 patient, T2 N1 in
17 patients, and T3 N1 in 1 patient. No tumor component was
found in the specimen of reoperation in 18 of 26 patients.
Histopathologically, the tumor reached immediately to the
resection margin of the first operation but not beyond it. The
mean interval between the first and second operations was 28
days (range, 8-89 days).
In the group with benign disease, there were 4 indications
because of early complication (within 30 days after the first
operation) of the initial procedure, which included 3 patients
with uncontrollable pneumonia that required an urgent resec-
tion to avoid septicemia and 1 patient with hemorrhagic
necrosis of the lung. The time intervals between the first and
second operations were 2, 8, 9, and 11 days. For all benign
indications, the mean interval between the first and second
operation was 133 months (range, 0-519 months).
Operative technique. Inclusion for completion pneu-
monectomy was restricted to patients with expected postop-
erative forced expiratory volume in 1 second of more than 1.0
L, as calculated by perfusion scintigraphy, and endurable car-
diac function. In case of a second primary malignant tumor
suspected preoperatively and in case of local recurrence
occurring more than 2 years after initial procedure, repeated
mediastinoscopy was performed as a rule to exclude N2 and
N3 disease.
We chose anterolateral thoracotomy as a rule, and the same
incision line as the initial operation was used for completion
pneumonectomy. The pericardium was open to dissect hilar
vessels when hilar adhesion was hard enough to dissect
extrapericardially. As a result, intrapericardial vessel ligation
was done in 41 (62%) patients. The bronchial stump was
manually sutured and covered with either intercostal muscle
or mediastinal fat in all patients who had received radiation
therapy after the initial operation (5 patients). Additional sur-
gical procedures were necessary in 7 (11%) patients: chest
wall resection in 3 patients; carinal resection in 2 patients;
pleuropneumonectomy in 1 patient; and pericardial resection
with insertion of prosthesis in 1 patient. The mean intensive
care unit stay was 4.4 days (range, 1-15 days). Mechanical
ventilation for more than 1 day was needed in 18 (27%)
patients (mean, 2.2 days; range, 1-10 days).
Statistical analysis. All intrahospital records of patients
were reviewed for clinical data, operative records were
reviewed for intraoperative problems, and intensive care unit
charts were reviewed for early postoperative complications.
The unpaired Student t test and the χ2 test were used for
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group comparison when appropriate. Survival was estimated
from the time of completion pneumonectomy with a Kaplan-
Meier model. The comparisons of survival between sub-
groups were made with the log-rank test.
Results
There were no intraoperative deaths and 5 (4 in
patients with benign indications and 1 in a patient
with a malignant indication) early postoperative
deaths within 30 days after the operation (mortality
rate, 7.6%). In 3 of these cases, completion pneu-
monectomy was done because of early complication of
the initial procedure. The cause of the deaths was mul-
tisystem failure caused by contralateral pneumonia in 3
patients, pulmonary embolism in 1 patient, and cardio-
genic shock caused by postoperative bleeding in 1
patient.
Complications after completion pneumonectomy
were encountered in 35 (53%) patients (Table II).
Complications occurred in 12 (71%) patients of the
group with benign indications and 23 (47%) patients of
the group with malignant indications, although this dif-
ference was not significant (P = .0923).
BPF was encountered in 5 (7.6%) patients, and
empyema was encountered in 7 (11%) patients. The
mean intervals between completion pneumonectomy
and BPF occurrence was 36 days (range, 6 days-4
months). One of 5 (20%) patients who received radia-
tion therapy before completion pneumonectomy had a
BPF, a higher rate than the 6.6% of patients who had
not. In 3 of 5 patients with BPFs, thoracostomas and
subsequent thoracoplasties were performed because
nonsurgical procedures were ineffective. There were no
statistically significant differences in the occurrence
rate of empyema between the group with benign indi-
cations (3/17 [18%] patients) and the group with malig-
nant indications (4/45 [8.9%] patients; P = .2739). The
bacteria detected in the empyema cavity were
Streptococcus species in 2 patients, Pseudomonas
species in 2 patients, and Acinetobacter and Candida
species in 1 patient each. In the remaining patient no
bacterium was detected.
Cardiac rhythm dysfunctions were encountered in 14
(21%) patients, all of which were classified as
supraventricular arrhythmia. The initial onset of
Table I. Relationship between indications of the first and second operation
Completion pneumonectomy
First operation No. Indication No.
Primary lung cancer 46 Incomplete resection 26
Local recurrence 12




Metastatic lung tumor 7 Metastatic lung tumor 5
Second primary lung cancer 1
Lung abscess 1
Bronchiectasis 5 Bronchiectasis 5
Carcinoid tumor 3 Local recurrence 2
Hemorrhagic necrosis 1
Tuberculosis 3 Tuberculosis 1
Bronchiectasis 1
Hemorrhagic necrosis 1
Bronchopulmonary aspergillosis 1 BPF 1
Other benign tumor 1 Bronchiectasis 1
Total 66 66
Table II. Details of postoperative complications
Type of complication No. %
Cardiac arrhythmia 14 21
Empyema 7 11
Postoperative bleeding 5 7.6
BPF 5 7.6
Pneumonia 3 4.5
Pulmonary edema 3 4.5
Sputum retention 2 3.0
Chylothorax 1 1.5
Pneumothorax 1 1.5
Recurrent nerve paralysis 1 1.5
Total (patient) 35 53%
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arrhythmia occurred between postoperative days 1 and
14 (median, day 2). These were all successfully treated
with digoxin and calcium blockers.
The mean operative time was 170 minutes (range, 67-
345 minutes), and the mean blood loss during the pro-
cedure was 805 mL (range, 100-3400 mL). The mean
blood loss in the group with benign indications was 973
mL, and that in the group with malignant indications
was 752 mL, although the difference was not statisti-
cally significant (P = .2219). Major blood vessel injury
occurred in 5 (7.6%) patients. The mean hospital stay
was 23 days (range, 14-184 days).
Follow-up was completed for all patients, and the
mean follow-up period of patients who survived more
than 30 days postoperatively was 4.5 years (range, 2-
115 months). Actuarial survival was calculated from
the time of completion pneumonectomy (Figs 1 and 2).
The actuarial 5-year survival was 57% for all 66
patients, 65% for patients with benign disease and 54%
for patients with malignant disease, without any differ-
ence between patients with benign disease and malig-
nant disease (P = .9478). We also analyzed survival
with regard to the indications in patients with malig-
nant disease. The actuarial 5-year survival was 60% for
the local recurrence group, 50% for the second prima-
ry tumor group, and 56% for the incomplete initial
resection group. The survival of the patient in the
metastatic lung tumor group has not reached 5 years.
There were no significant differences between groups
(P = .4288).
Discussion
Completion pneumonectomy is a challenging proce-
dure that poses a great stress on surgeons not only
intraoperatively but also preoperatively and postopera-
tively. The surgeon cannot be too careful in deciding
whether the operation is indeed indicated, whether the
gain in survival and quality of life outweighs the risks
involved, and whether other therapeutic options are
available, as stated by Deslauriers.9
Snijder and colleagues10 classified residual tumor as
carcinoma in situ (CIS), mucosa residual disease
(MRD), peribronchial residual disease (PRD), or lym-
phatic infiltration. They concluded that patients with
invasive tumors (MRD+PRD) have a high incidence of
local recurrence and that such tumors have an adverse
effect on survival. In their series the 5-year survival in
the complete resection group was 54%, whereas our
result in the same group was 56%. According to this
classification, our patients had no CIS, 5 had MRD, 10
had PRD, and 11 had lymphatic infiltration (positive
N1 lymph node that could not be extirpated with a cap-
sule). Our policy is that patients with either CIS or
invasive tumor, including lymphatic infiltration at the
resection margin, should undergo reoperation, espe-
cially for early-stage lung cancer, whenever their con-
ditions are tolerable. As to lymphatic infiltration, if the
lymph node is extirpated with a capsule and R0 resec-
tion can be achieved, we will not go so far as pneu-
monectomy because no superiority of pneumonectomy
to lobectomy has been observed for N1 disease.11,12
Fig 1. Analysis of survival related to indications for completion pneumonectomy.
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In our results the patient group that underwent com-
pletion pneumonectomy for an early complication of
initial procedure showed significantly higher mortality
(3/4 [75%] patients). As suggested by Muysoms and
colleagues,3 who reported a mortality rate of 37.5% for
the same indication, completion pneumonectomy
should be performed for this group only if there is no
alternative method of therapy and only after sincere
explanations to patients and families of this extremely
high risk.
Resection of pulmonary metastases by means of
pneumonectomy remains under discussion. Our data
are perhaps too minimal to induce any conclusions, but
the presence of survivors over 4 years suggests that the
procedure should not be considered an absolute con-
traindication if the patients are selected by means of
strict criteria.13 Our criteria for eligibility included the
following: motivated patients under 70 years old; stabi-
lized primary tumor; absence of mediastinal lymphade-
nomegaly detected by means of computed tomography;
no extrathoracic metastases at the time of thoracotomy;
acceptable cardiorespiratory reserve; and no alternative
treatment other than operation.
Completion pneumonectomy for bronchiectasis is
said to be a relatively high-risk procedure, and its mor-
tality can be as high as 43%.14 However, the mortality
rate in our series was 0%, and the severe complication
(BPF) occurred in 14% of the patients. These figures
were acceptable, taking into consideration that we
included the emergency case of uncontrollable bleed-
ing. Complete resection of the affected segments is
most important for the avoidance of a second opera-
tion. All of our patients had undergone complete resec-
tion at the initial operation, but new lesions, which
could not be detected by bronchography before,
appeared over 20 years.
Repeated mediastinoscopy may be effective in
restricting cases of second primary lung cancer and
metastatic lung tumor to inclusion to exclude N2 and
N3 disease, which is afforded little benefit with this
risky operation.
Radiation therapy precedes the hilar adhesion and
may obliterate the intrapericardial plane, which makes
the operation more difficult. We should consider the
possibility of having to reoperate on a patient who has
had complete resection of lung cancer before postoper-
ative radiation therapy because the effectiveness of it is
not clear.4 Deslauriers9 reported the “bronchus first”
technique in case of severe hilar adhesion. This tech-
nique may especially be effective in completion pneu-
monectomy after radiation therapy, but we did not need
to use it for the cases reported.
Complications after completion pneumonectomy are
common. The complication rate of our data was 53%,
a little higher than those reported previously (18%-
46%).2-7 This is probably because of our inclusion of
nonsevere arrhythmia, as detected by Holter electrocar-
diography recording in our intensive care unit. We
Fig 2.  Analysis of survival in the group with malignant indications. LR, Local recurrence; IR, incomplete resec-
tion; SP, second primary lung cancer; MT, metastatic lung tumor.
observed postoperative supraventricular arrhythmia in
21% of the patients. Some authors stated that the extent
of pulmonary resection was correlated with the devel-
opment of this type of arrhythmia,15 whereas others
observed the strong relationship of arrhythmia only
with pneumonectomy (incidence, 46.1%).16 In any
case, we recommend the prophylactic treatment of the
patient who is planning on undergoing completion
pneumonectomy.
BPFs occurred in 5 (7.6%) patients, 4 of which were
on the right side, 1 of which occurred with preopera-
tive radiation, and 1 of which occurred on the left side
with preoperative severe infection. This rate is similar
to those of previous reports (0%-13%).2-7 In our series
there was no significant difference of the BPF occur-
rence rate between the group with benign disease and
that with malignant disease, as opposed to the results
of previous reports. We have routinely covered the
bronchial stump with a flap of intercostal muscle or
mediastinal fat in case of right side and preoperative
radiotherapy.17 In addition, covering of the bronchial
stump of the patients with preoperative infection is
recommended.
As to empyema, we have not observed any signifi-
cant difference in the occurrence rate between
patients with preoperative infection and patients with-
out it (13% vs 10%, P = .6964). Patients with preop-
erative infection can be successfully managed with
preoperative prophylactic antibiotic therapy, intensive
respiratory physiotherapy, intraoperative stump-cov-
ering technique, and postoperative washing of the tho-
racic cavity through drainage, which should be kept in
place until the thoracic cavity proves to be sterile
postoperatively. Al-Kattan and Goldstraw5 advised an
additional surgical procedure, such as a limited thora-
coplasty with a use of an omental or muscle flap, for
cases involving infection.
Contralateral pneumothorax may potentially be a
life-threatening complication. The possibility of such
an occurrence would be higher because mechanical
ventilation is frequently and for a longer time used for
respiratory failure after pneumonectomy. We must
carefully check contralateral pneumothorax by means
of daily roentgenography in addition to contralateral
pneumonia.
Chylothorax develops in 0.2% to 0.5% of cardiovas-
cular and thoracic operations,18 and its occurrence after
pneumonectomy is rare. We must, however, pay atten-
tion to the excessive and rapid filling of the postpneu-
monectomy space in the early postoperative period,
which may be due to bleeding, infection, and chylotho-
rax.19 Chylothorax should be treated early by means of
a surgical invention because it can easily deteriorate the
hemodynamic and respiratory state of a patient after
pneumonectomy. Our patients with this complication
showed rapid filling of the thoracic cavity and needed
a surgical procedure to control the chylous leak at post-
operative day 5.
Completion pneumonectomy should be done by
skilled thoracic surgeons. Major technical difficulties
in operations exist in the dissection of the pleural
adhesion, which sometimes needs to be done through
the extrapleural plane. Major blood vessel injury
occurred in 5 (7.6%) patients, and the mean bleeding
volume was 805 mL. These values are lower than
those in most previous reports (3.8%-16.2% and 950-
2019 mL each),2-7 which perhaps is a result of our
inclusion of the incomplete resection group, which had
a smaller interval between the first and second opera-
tion and consequently had a significantly lower bleed-
ing volume than the rest of the groups (563 mL vs 978
mL, P = .0061).
In contrast to a previous report,2 we did not observe
any difference in postoperative mortality between
patients with benign disease and malignant disease.
The mortality rate in our series was 7.6%, which is
comparable with the figures shown for standard pneu-
monectomy in the literature.20
In our study we showed an overall 5-year survival of
54% among patients with malignant disease. This high
survival compared with the rate of 23% to 44.5%
reported previously5-12 was probably related to the
inclusion of patients in the incomplete initial resection
group, most of whom had early stage lung cancer.
Nonetheless, these favorable long-term results justify
the procedure for the treatment of disease with severe
prognosis.
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